MERIDIA

Compare MERIDIA  to:
Compare
Compare

Generic Name for MERIDIA

Sibutramine HCl monohydrate 5mg, 10mg, 15mg; caps.

Legal Classification:

CIV

Pharmacological Class for MERIDIA

Mixed neurotransmitter reuptake inhibitor.

Manufacturer of MERIDIA

Abbott Laboratories

Indications for MERIDIA

Adjunct to diet in the management of obesity in patients with initial body mass index ≥30kg/m2, or ≥27kg/m2 in presence of other risk factors.

Adult dose for MERIDIA

≥16years: Initially 10mg once daily. After 4 weeks, may titrate to 15mg once daily.

Children's dosing for MERIDIA

<16years: not recommended.

Contraindications for MERIDIA

History of coronary artery disease (eg, angina, MI), CHF, tachycardia, arrhythmias, cerebrovascular (eg, stroke, TIA) or peripheral arterial occlusive disease. Inadequately controlled hypertension >145/90mm Hg. Over 65 years of age. During or within 2 weeks of MAOIs (eg, phenelzine, selegiline) or concomitant centrally-acting appetite suppressants. Anorexia or bulimia nervosa.

Precautions for MERIDIA

Exclude organic causes of obesity. Severe renal or hepatic dysfunction: not recommended. Do initial BP and pulse; monitor regularly during therapy; consider discontinuing or reducing dose for patients with sustained increases in either BP or pulse. Seizures (discontinue if occur). Hypertension. Narrow-angle glaucoma. Bleeding disorders. Elderly. Pregnancy (Cat.C), nursing mothers: not recommended.

Interactions for MERIDIA

See Contraindications. Avoid other serotonergic drugs (eg, SSRIs, venlafaxine); monitor if used together; possible serotonin syndrome with these and with sumatriptan, dihydroergotamine, some opioids (eg, dextromethorphan, meperidine, pentazocine, fentanyl), lithium, or tryptophan. Caution with other CNS-active drugs or drugs that can raise BP or pulse (eg, decongestants). Possible interaction with ketoconazole, erythromycin, others metabolized by CYP3A4. Excessive alcohol: not recommended. Caution with oral anticoagulants, platelet inhibitors.

Adverse Reactions for MERIDIA

Dry mouth, anorexia, insomnia, constipation, headache, increased appetite, dizziness, nervousness, GI upset, gallstones, increased BP and/or pulse, mydriasis, others.

How is MERIDIA supplied?

Caps—30

Related Disease:

Obesity

Related Resources

Exel/Exelint infusion set needles recalled

January 26, 2010

FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets, and Exel/Exelint "Securetouch+" Safety Huber Infusion Sets due to 'coring,' the cutting or dislodging of silicone cores or slivers from the ports into which they are inserted).

Updated warning on counterfeit Alli dosing

January 25, 2010

The FDA is updating its warning about a counterfeit version of Alli (orlistat caps, from GlaxoSmithKline) that does not contain orlistat, rather sibutramine, a prescription product indicated as an adjunct to diet in the management of obesity.

Meridia cardiovascular safety review update

January 21, 2010

The FDA has notified healthcare professionals that the review of additional data indicates an increased risk of heart attack and stroke in patients with a history of cardiovascular disease using Meridia (sibutramine HCl tablets, from Abbott).

FDA warns of counterfeit Alli for weight loss

January 19, 2010

The FDA has warned consumers about a counterfeit and potentially harmful version of over-the-counter Alli (orlistat caps, from GlaxoSmithKline), indicated for use as an adjunct to reduced-calorie, low-fat diet for weight loss in overweight adults.

NDA submitted for Qnexa for obesity

December 29, 2009

Vivus announced that a New Drug Application (NDA) has been submitted to the FDA seeking approval of Qnexa (phentermine and topiramate, from Vivus) for the treatment of obesity, including weight loss and maintenance of weight loss, in patients who are obese or overweight with co-morbidities such as hypertension, type 2 diabetes, dyslipidemia or central adiposity.